Skip to main content
Smart Investors Daily
UT

NASDAQ · UTHR

United Therapeutics Corporation

Healthcare · Biotechnology

$559.10

Down-$18.24 (-3.16%)

Updated Nov 20, 2026, 2:15 AM

SID Score

7.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap
21.83B
P/E ratio
16.83
Dividend yield
0.00%
52-week range
$455.63 – $614.23
Volume
393.76K
Avg. volume
627.5K

Price performance · UTHR

UTHR price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

UTHR closed at $559.10 after 21 trading sessions, down 4.39% for the selected period.

Last close
$559.10
Period change
-4.39%
Period low
$559.10
Period high
$608.49
Daily close
View OHLC price history
UTHR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$577.63$578.80$554.48$559.10393.76K
Nov 18, 2026$581.43$588.43$569.335$577.34433.87K
Nov 17, 2026$584.96$590.94$575.41$584.10424.48K
Nov 16, 2026$592.27$595.66$578.71$587.88441.67K
Nov 13, 2026$593.31$598.84$587.00$591.17463.51K
Nov 12, 2026$597.50$598.38$586.56$593.31338.73K
Nov 11, 2026$588.36$598.80$583.80$595.66369.69K
Nov 10, 2026$580.07$593.10$577.26$588.61461.37K
Nov 9, 2026$570.47$586.46$556.63$582.46571.82K
Nov 6, 2026$561.95$569.4499$559.41$562.02468.56K
Nov 5, 2026$608.29$608.29$561.24$565.72619.73K
Nov 4, 2026$583.63$614.23$578.2801$608.49946.06K
Nov 3, 2026$596.14$606.72$596.14$601.32611.88K
Nov 2, 2026$596.54$600.895$592.465$596.13419.87K
Oct 30, 2026$600.00$609.99$593.57$598.72518.24K
Oct 29, 2026$591.76$599.45$589.615$593.54370.34K
Oct 28, 2026$581.94$589.19$581.875$586.48421.67K
Oct 27, 2026$587.10$593.00$582.665$591.20457.45K
Oct 26, 2026$589.11$593.50$584.495$592.84577.01K
Oct 23, 2026$584.92$590.98$576.24$587.50637.88K
Oct 22, 2026$568.69$590.79$562.855$584.79895.46K

Latest UTHR news

The latest Smart Investors Daily articles mentioning UTHR.

UTHR research

Overview

Company profile and research snapshot.

Company profile

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$539.83
Implied upside
—
Analysts
21
UTHR recent ratings
DateFirmRatingTarget
Nov 5, 2026TD CowenBuy—
Nov 5, 2026RBC CapitalOutperform—
Nov 5, 2026Wells FargoOverweight—
Nov 4, 2026BTIGBuy—
Oct 28, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

Liquidia (LQDA) Stock Looks Rich Relative To Its Earnings Power

Liquidia has delivered a very strong share price run in recent years, and with the stock last closing at US$47.87 the key question is whether that price can be explained by the company’s earnings power. After such a move, you need to ask if the story in the income statement keeps up with the story in the chart. Over the past 5 years the stock has returned about 885.0%, which puts a lot of weight on whether current earnings can justify this kind of rerating. The recent legal settlement with...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.